Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
PetMedix logo — R&D stage veterinary therapeutics biotechnology company base...

PetMedix

R&D stage veterinary therapeutics biotechnology company based in Cambridge, UK

Founded 2017 United Kingdom Cambridge, United Kingdom 16 employees Series B Total: $37.00M Biotechnology, Health Care

General Information

Company Name PetMedix
Founded Year 2017
Location United Kingdom Cambridge, United Kingdom
Employees 16
Industries Biotechnology, Health Care
Funding Stage Series B
Business Model B2B, Platform, White Label
Revenue Model Product Sales, Licensing, Value Based Pricing
Social

BounceWatch is an independent company data service, not affiliated with PetMedix. To contact PetMedix, visit petmedix.co.uk.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does PetMedix compare?

A PDF of PetMedix and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting PetMedix soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About PetMedix

PetMedix, recognized as an R&D stage veterinary therapeutics biotechnology company, is situated in Cambridge, UK. Founded in 2017, the company has carved a niche in the Biotechnology and Health Care sectors, specializing in innovative treatments for animals.

The company recently announced an upcoming collaboration with Zoetis, a significant transition that may enhance its offerings and market reach.

In terms of funding, PetMedix secured a robust £27.00M Series B investment on 08 September 2021, drawing the attention of prominent investors such as Parkwalk Advisors, Cambridge Innovation Capital, Digitalis Ventures, Kyoritsu Corporation, and Tencent. Such backing underscores the confidence in PetMedix's potential for growth and innovation within the veterinary biotechnology space.

Business keywords: biotech, veterinary, therapies, scientific methods, pet well-being, longevity, contentment

Services & Products

Development of species-specific therapeutic antibodies
Biotechnology platform for veterinary medicine
Research and development in pet disease treatment

Target Customers

Veterinarians Pet owners Veterinary pharmaceutical companies

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series B £27.00M 5
Parkwalk Advisors Cambridge Innovation Capital Digitalis Ventures
Parkwalk Advisors, Cambridge Innovation Capital +3
08 Sep 2021
Series A £10.00M 3
Parkwalk Advisors Companion Fund Digitalis Ventures
Parkwalk Advisors, Companion Fund +1
25 Feb 2019

PetMedix Alternatives & Competitors

View All Alternatives
PetMedix vs
GoodCell
GoodCell United States

Founded in 2016, GoodCell’s mission is to empower people to live longer, healthier lives by using th...

Seed
9 employees
Biotechnology, Health Care
PetMedix vs
Assisi Animal Health
Assisi Animal Health United States

Safe, FDA-cleared, and clinically-proven technology for treating pain, inflammation, and behavior di...

11 employees
Biotechnology, Health Care
PetMedix vs
SmartCella Holding AB
SmartCella Holding AB Sweden

SmartCella is a global biopharma company with a vision to revolutionize targeted therapeutic deliver...

72 employees
Biotechnology, Health Care
View all alternatives

FAQ About PetMedix

R&D stage veterinary therapeutics biotechnology company based in Cambridge, UK
PetMedix was founded in 2017.
PetMedix is headquartered in Cambridge, United Kingdom.
PetMedix operates in Biotechnology and Health Care. Its work centres on biotech, veterinary, therapies and scientific methods. Its customers include Veterinarians, Pet owners and Veterinary pharmaceutical companies.
PetMedix has a B2B, Platform and White Label business model. Its revenue comes from Product Sales, Licensing and Value Based Pricing.
PetMedix has approximately 16 employees.
PetMedix has completed 2 funding rounds, raising a total of $37.00M. The latest funding stage is Series B.
PetMedix offers: Development of species-specific therapeutic antibodies, Biotechnology platform for veterinary medicine, Research and development in pet disease treatment.
Top alternatives and competitors to PetMedix include GoodCell, Assisi Animal Health, SmartCella Holding AB, Zoetis, Olema Oncology. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
PetMedix and GoodCell are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for PetMedix, https://bouncewatch.com/company/petmedix, updated 22 July 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes